Caris Life Sciences (NASDAQ:CAI – Get Free Report) and OmniAb (NASDAQ:OABI – Get Free Report) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, institutional ownership, profitability, analyst recommendations, earnings, dividends and risk.
Profitability
This table compares Caris Life Sciences and OmniAb’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Caris Life Sciences | 9.16% | 16.00% | 8.05% |
| OmniAb | -108.11% | -16.74% | -14.79% |
Valuation and Earnings
This table compares Caris Life Sciences and OmniAb”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Caris Life Sciences | $812.03 million | 8.65 | -$68.09 million | $0.33 | 74.21 |
| OmniAb | $18.67 million | 39.84 | -$64.78 million | ($0.34) | -15.00 |
OmniAb has lower revenue, but higher earnings than Caris Life Sciences. OmniAb is trading at a lower price-to-earnings ratio than Caris Life Sciences, indicating that it is currently the more affordable of the two stocks.
Insider and Institutional Ownership
72.1% of OmniAb shares are owned by institutional investors. 50.0% of Caris Life Sciences shares are owned by company insiders. Comparatively, 9.8% of OmniAb shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Analyst Recommendations
This is a summary of current ratings and price targets for Caris Life Sciences and OmniAb, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Caris Life Sciences | 1 | 5 | 8 | 0 | 2.50 |
| OmniAb | 1 | 0 | 3 | 0 | 2.50 |
Caris Life Sciences presently has a consensus target price of $31.18, indicating a potential upside of 27.32%. OmniAb has a consensus target price of $11.50, indicating a potential upside of 125.49%. Given OmniAb’s higher probable upside, analysts plainly believe OmniAb is more favorable than Caris Life Sciences.
Volatility and Risk
Caris Life Sciences has a beta of 0.71, indicating that its share price is 29% less volatile than the S&P 500. Comparatively, OmniAb has a beta of 0.6, indicating that its share price is 40% less volatile than the S&P 500.
Summary
Caris Life Sciences beats OmniAb on 9 of the 13 factors compared between the two stocks.
About Caris Life Sciences
Caris Life Sciences is a precision medicine company that develops molecular profiling and artificial intelligence technologies to support cancer diagnosis and treatment decisions. Its services analyze the biological characteristics of a patient’s tumor to help physicians identify information that may guide care. The company’s offerings include tumor profiling based on DNA and RNA analysis, as well as blood-based testing. Caris also provides molecular data and research services to biopharmaceutical companies to support drug development and the study of cancer.
About OmniAb
OmniAb, Inc. is a biotechnology company that develops antibody discovery technologies for use in creating therapeutic medicines. It works with pharmaceutical and biotechnology companies to identify and advance antibody candidates for potential drug development. Its platform includes genetically engineered animals that can produce antibodies with human characteristics, along with related discovery and screening technologies. These tools are designed to help partners find antibodies for a range of therapeutic targets and applications.
Receive News & Ratings for Caris Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Caris Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
